#clinical pipeline
2 stories
Addex Therapeutics Cash Runway at Risk
Addex Therapeutics' cash runway shrinks as it regains GABAB rights and faces funding pressure.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Can Zenas BioPharma justify its $108M quarterly burn?
A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 2m